Link a Progetto e CV;Codice ;Responsabile scientifico;Istituzione;Titolo dello studio;Budget Finanziato da Contratto (€);; http://www.aifa.gov.it/sites/default/files/2_Corrado_Barbui_Bando_2016.pdf;AIFA-2016-0234923;Corrado Barbui;Dipartimento di neuroscienze, biomedicina e movimento dell'Università degli Studi di Verona;Assessing safety and efficacy of Vortioxetine versus SSRIs in elderly patients with depression: a pragmatic, multicenter, open-label, parallel-group, superiority, randomized trial (Version 3, 05/12/2016). VESPA study: Vortioxetine in the Elderly vs. SSRIs: a Pragmatic Assessment.;680.500,00;; http://www.aifa.gov.it/sites/default/files/3_Alfredo_Berruti_Bando_2016.pdf;AIFA-2016-02364512;Alfredo Berruti;ASST degli Spedali Civili di Brescia;Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Adrenocortical CarcInomA with high risk of recurrence (Trial ACACIA);378.000,00;; http://www.aifa.gov.it/sites/default/files/Bianchi_Maria_Luisa_2016.pdf;AIFA-2016-02364539;Maria Luisa Bianchi;Istituto Auxologico Italiano;Glycogen Storage Disease Type I And Bone: Identification Of Risk Factors For Bone Loss And Fractures;275.000,00;; http://www.aifa.gov.it/sites/default/files/Blandini_Fabio_2016.pdf;AIFA-2016-02364594;Fabio Blandini;Fondazione Istituto Neurologico Nazionale Casimiro Mondino;Biological Markers Of Frailty In The Physiological And Pathological Aging Brain: Correlations With Pharmacological Frailty;650.200,00;; http://www.aifa.gov.it/sites/default/files/6_Mario_Boccadoro_Bando_2016.pdf;AIFA-2016-02364784;Mario Boccadoro;Università degli Studi di Torino;A Randomized, multicEnter, open lAbel study comparing two standard treatments, bortezomib-melpahlan-prednisone (VMP) vs lenalidomide-dexamethasone (Rd) in eLderly community population affected by multiple myeloma (MM);337.040,00;; http://www.aifa.gov.it/sites/default/files/7_Marco_Cattaneo_Bando_2016.pdf;AIFA-2016-02364723;Marco Cattaneo;Dipartimento di Scienze della Salute, Università degli Studi di Milano, Ospedale San Paolo;Pharmacokinetics And Pharmacodynamics Of Acethylsalicylic Acid In High-Risk Pregnancy;479.469,61;; http://www.aifa.gov.it/sites/default/files/8_Maria_Gisella_Cavallo_Bando-2016.pdf;AIFA-2016-02364864;Maria Gisella Cavallo;Sapienza Università di Roma;A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to address a gender-specific frailty. The SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) study;496.389,00;; http://www.aifa.gov.it/sites/default/files/9_Gianluigi_Condorelli_Bando_2016.pdf;AIFA-2016-02364544;Gianluigi Condorelli;IRCCS Istituto Clinico Humanitas;Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controlled trial;466.092,24;; http://www.aifa.gov.it/sites/default/files/10_Alessandra_Consolaro_Bando_2016.pdf;AIFA-2016-02364494;Alessandro Consolaro;IRCCS Giannina Gaslini;Comparison of STep-Up and step-Down therapeutic strategies in Childhood Arthritis;146.957,14;; http://www.aifa.gov.it/sites/default/files/11_Andrea_De_Censi_Bando_2016.pdf;AIFA-2016-02364326;Andrea De Censi;E.O Galliera;Exemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A randomized phase III Trial, expert. ;1.101.108,00;; http://www.aifa.gov.it/sites/default/files/12_Giovanni_De_Gaetano_Bando_2016.pdf;AIFA-2016-02364690;Giovanni De Gaetano;Fondazione Neuromed;Polypharmacy and the Elderly: Prevalence, Clinical Impact and Epigenetic Changes in the Population-based Cohort of the Moli-sani study;1.194.050,00;; http://www.aifa.gov.it/sites/default/files/13_Elisabetta_Dejana_Bando_2016.pdf;AIFA-2016-02364593;Elisabetta Dejana;IFOM Fondazione Istituto FIRC di Oncologia Molecolare;A multicenter randomized clinical trial on propranolol in Familial Cerebral Cavernous Malformation;761.748,40;; http://www.aifa.gov.it/sites/default/files/15_Elisabetta_Ferretti_Bando_2016.pdf;AIFA 2016-02364976;Andres J.M. Ferreri;IRCCS Ospedale San Raffaele;Randomized phase II Trial on fitness - and comorbidity - tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma;423.773,54;; http://www.aifa.gov.it/sites/default/files/15_Elisabetta_Ferretti_Bando_2016.pdf;AIFA-2016-02365049;Elisabetta Ferretti;Sapienza Università di Roma;Circulating microRNAs and DNA (cfDNA) as novel biomarkers for diagnostic, prognostic and therapeutic use in Medullary Thyroid Carcinoma ;983.497,87;; http://www.aifa.gov.it/sites/default/files/16_Roberto_Gambari_Bando_2016.pdf;AIFA-2016-02364887;Roberto Gambari;Dipartimento di Scienze della Vita e Biotecnologie - Università di Ferrara;TREATMENT OF BETA-THALASSEMIA PATIENTS WITH RAPAMYCIN (SIROLIMUS): FROM PRE-CLINICAL RESEARCH TO A CLINICAL TRIAL;856.000,00;; http://www.aifa.gov.it/sites/default/files/17_Marina_Garassino_Bando_2016.pdf;AIFA-2016-02364595;Marina Garassino;Fondazione IRCCS Istituto Nazionale dei Tumori;Improving treatment strategies in Thymic Epithelial Tumors: a TYME collaborative effort;1.552.717,00;; http://www.aifa.gov.it/sites/default/files/18_Loreto_Gesualdo_Bando_2016.pdf;AIFA-2016-02365060;Loreto Gesualdo;Università degli Studi di Bari Aldo Moro ;Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 parallel arms randomized controlled trial;2.113.000,00;; http://www.aifa.gov.it/sites/default/files/19_Chiara_Maria_Grana_Bando_2016.pdf;AIFA-2016-02364782;Chiara Maria Grana;Istituto Europeo di Oncologia S.r.l.;Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumours.;549.733,63;; http://www.aifa.gov.it/sites/default/files/Locatelli_Franco_2016.pdf;AIFA-2016-02364631;Franco Locatelli;Ospedale Pediatrico Bambino Gesù, IRCCS;First-in-human Italian Phase I-II Trial based on adoptive Chimeric Antigen receptor (CAR)-Tcells specific for GD2 antigen in patients with high-risk neuroblastoma (HR NB);500.000,00;; http://www.aifa.gov.it/sites/default/files/21_Aurelio_Maggio_Bando_2016.pdf;AIFA-2016-02364612;Aurelio Maggio;Fondazione Franco e Piera Cutino Onlus;Multicentric Randomized Clinical Trial of Deferasirox-Deferiprone Sequential Therapy versus Deferasirox or Deferiprone;386.290,00;; http://www.aifa.gov.it/sites/default/files/23_Jessica_Mandrioli_Bando_2016.pdf;AIFA-2016-02364678;Jessica Mandrioli;Azienda Ospedaliero-Universitaria di Modena ;Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial;990.600,00;; http://www.aifa.gov.it/sites/default/files/24_Paolo_Manzoni_Bando_2016.pdf;AIFA-2016-02364386;Paolo Manzoni;Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ;Randomized, multi-center, open-label study on Respiratory SEquelae after RSV Bronchiolitis in PREterm babies (PRESERV);600.000,00;; http://www.aifa.gov.it/sites/default/files/25_Lucia_Margari_Bando_2016.pdf;AIFA-2016-02365052;Lucia Margari;Università degli Studi di Bari Aldo Moro (Dipartimento Scienze Mediche di Base Neuroscienze ed Organi di Senso);Multi-centre, randomised, open label pragmatic label to compare the effectiveness and safety of interferon-beta 1a (IFN beta 1a) weekly i.m and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis;439.950,00;; http://www.aifa.gov.it/sites/default/files/26_Roberto_Massa_Bando_2016.pdf;AIFA-2016-02364987;Roberto Massa;Università degli studi di Roma Tor Vergata;EFFICACY OF METFORMIN ON MOTILITY AND STRENGTH IN MYOTONIC DYSTROPHY TYPE 1. A randomized, double blind, placebo-controlled, multicenter clinical trial.;401.600,00;; http://www.aifa.gov.it/sites/default/files/27_Piero_Parchi_Bando_2016.pdf;AIFA-2016-02364982;Piero Parchi;Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Alma Mater Studiorum Università di Bologna;OXYTOCIN RESEARCH FOR BEHAVIORAL IMPAIRMENT SYMPTOMS IN DEMENTIA: Potential clinical efficacy of intranasal oxytocin in the treatment of frontotemporal dementia. A randomized, double-blind, placebo-controlled crossover trial.;173.256,15;; http://www.aifa.gov.it/sites/default/files/28_Massimo_Mauri_Bando_2016.pdf;AIFA-2016-02364852;Massimo Mauri;Fondazione IRCCS CA' GRANDA Ospedale Maggiore Policlinico;Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study. (CAT-PSY);488.792,11;; http://www.aifa.gov.it/sites/default/files/29_Giovanni_Montini_Bando_2016.pdf;AIFA-2016-02364896;Giovanni Montini;Fondazione IRCCS CA' GRANDA Ospedale Maggiore Policlinico;A Phase 2 Open-Label Study To Evaluate The Efficacy Of Allogeneic Human Cord Blood-Derived Mesenchymal Stromal Cells In Maintaining Remission After Immunosuppressive Therapy Withdrawal In Pediatric Patients With Steroid-Dependent Nephrotic Syndrome;840.855,20;; http://www.aifa.gov.it/sites/default/files/30_Eduardo_Nobile_Orazio_Bando_2016.pdf;AIFA-2016-02364540;Eduardo Nobile Orazio;IRCCS Istituto Clinico Humanitas;A randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a study based on the Italian Database of CIDP patients;697.323,27;; http://www.aifa.gov.it/sites/default/files/31_Giovanni_Palladini_Bando_2016.pdf;AIFA-2016-02364602;Giovanni Palladini;Fondazione I.R.C.C.S. Policlinico San Matteo;A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy-TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transthyretin;647.298,00;; http://www.aifa.gov.it/sites/default/files/32_Alberto_Papi_Bando-2016.pdf;AIFA-2016-02364957;Alberto Papi;Dipartimento di Scienze Mediche Università di Ferrara;Comparison of 1-year treatment with inhaled bronchodilators (labd) plus inhaled glucocorticosteroids (ics) versus labd without ics on re-hospitalizations and/or death in elderly patients with chronic obstructive pulmonary disease (copd) recently hospitalized because of an acute exacerbation of copd (icslife);2.946.318,00;; http://www.aifa.gov.it/sites/default/files/33_Giancarlo_Parenti_Bando_2016.pdf;AIFA-2016-02364305;Giancarlo Parenti;Dipartimento di Scienze mediche traslazionali dell'Università degli Studi di Napoli Federico II;Micro-Rna As Novel Biomarkers For Lysosomal Storage Diseases;234.500,00;; http://www.aifa.gov.it/sites/default/files/33_Maria_Teresa_Pellecchia_Bando_2016.pdf;AIFA-2016-02364714;Maria Teresa Pellecchia;Università degli Studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”;Gender-related predictors of development of fluctuations and dyskinesia in Parkinson's disease: a 2-year observational longitudinal study;815.595,00;; http://www.aifa.gov.it/sites/default/files/35_Flora_Peyvandi_Bando_2016.pdf;AIFA-2016-02365016;Flora Peyvandi;Fondazione IRCCS CA' GRANDA Ospedale Maggiore Policlinico;Inhibitor development in previously untreated patients with severe hemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product:an international, multicenter, prospective, controlled, randomized, open label, clinical trial, SIPPET 2;630.500,00;; http://www.aifa.gov.it/sites/default/files/Pinto_Antonio_2016.pdf;AIFA-2016-02364973;Antonio Pinto;Fondazione Italiana Linfomi Onlus;A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL);374.684,00;; http://www.aifa.gov.it/sites/default/files/37_Nicolo_Pipitone_Bando_2016.pdf;AIFA-2016-02364869;Nicolò Pipitone;Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia;Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis;326.849,00;; http://www.aifa.gov.it/sites/default/files/38_Massimo_Rambaldi_Bando_2016.pdf;AIFA-2016-02364730;Alessandro Rambaldi;Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII;Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy after Hapoidentical Stem Cell Transplantationem Cell Transplantation;392.150,20;; http://www.aifa.gov.it/sites/default/files/39_Giovanni_Ristori_Bando-2016.pdf;AIFA-2016-02365063;Giovanni Ristori;Dipartimento di neuroscienze, salute mentale e organi di senso dell’Università Sapienza di Roma;Riluzole in patients with spinocerebellar ataxia type 7: a randomized , double-blind, placebo-controlled pilot trial with a lead in phase.;275.980,00;; http://www.aifa.gov.it/sites/default/files/40_Gianni_Soraru_Bando_2016.pdf;AIFA-2016-02364843;Gianni Sorarù;Azienda Ospedaliera di Padova;A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients With Spinal and Bulbar Muscular Atrophy (SBMA).;604.726,80;; http://www.aifa.gov.it/sites/default/files/41_Marina_Vivarelli_Bando_2016.pdf;AIFA-2016-02364623;Marina Vivarelli;IRCCS Ospedale Pediatrico Bambino Gesù;A prospective study to assess safety and efficacy of the use of bone-marrow derived MESenchymal stromal cells as immunomodulatory therapy for children and young adults with severe and difficult-to-treat frequently relapsing or steroid-dependent idiopathic NEPHrotic syndrome: the MESNEPH study;515.200,00;; ;;;;;;; ;;;;;;;